DENVER, March 21, 2014 (GLOBE NEWSWIRE) -- Janus Capital Group Inc. (NYSE:JNS) today announced Janus Global Life Sciences Fund received 2014 Lipper Fund Awards as the Best Global Health/Biotechnology Fund for the three, five and 10-year periods (Class I, D and D shares respectively) ending Dec. 31, 2013.
"Lipper's recognition of Janus Global Life Sciences Fund reinforces the value of our fundamental, bottom-up investment approach," said Enrique Chang, CIO of Equities and Asset Allocation with Janus. "Our approach to risk-management and diversification helped the Fund navigate the market swings of the past 10 years while continuing to produce terrific results for clients."
The Lipper Awards honor fund management firms and individual mutual funds that excel in delivering consistently strong, risk-adjusted performance relative to their peers. Annual Lipper Awards reflect consistency of return over time. They take into account both short- and long- term risk-adjusted performance relative to a fund's classification and look back over a variety of holding periods.
"Janus Capital Management has been deservedly recognized for the performance of its Janus Global Life Sciences Fund which stood apart from its peers by impressively winning the 2014 Lipper Fund Award for all three eligible time periods in the global health/biotechnology classification," said Barry Fennell, senior research analyst with Lipper. "The awards are certainly a positive reflection of the investment process that Janus has in place in the global health/biotechnology sectors."
Janus Global Life Sciences Fund seeks to identify high quality or improving businesses in the life sciences sector that trade at a discount to our estimate of intrinsic value. The fund uses the power of Janus' deep fundamental research to seek opportunities across the health care spectrum and around the world, with a strong focus on businesses that address unmet medical needs or make the health care system more efficient.
"Our investment approach is rooted in the belief that the greatest value creation comes when innovation meets rising demand," said Portfolio Manager Andy Acker. "We believe the rapid advances taking place in biotechnology, the needs of an aging population, and the desire to control costs will have major implications for the health care sector. This should present a number of compelling investment opportunities over the next decade."
About Janus Capital Group Inc.
Janus Capital Group Inc. (JCG) is a global investment firm dedicated to delivering better outcomes for clients through differentiated investment solutions from three independent managers: Janus Capital Management LLC (Janus), INTECH Investment Management LLC (INTECH) and Perkins Investment Management LLC (Perkins). Each manager brings a distinct perspective, style-specific expertise and a disciplined approach to risk. JCG's multi-boutique approach provides clients with distinctive solutions across a broad range of asset classes including equities, fixed income, alternatives, asset allocation and income products.
At the end of December 2013, JCG managed approximately $173.9 billion in assets for shareholders, clients and institutions around the globe. Based in Denver, JCG also has offices in London, Milan, Munich, Singapore, Hong Kong, Tokyo, Melbourne, Paris, The Hague, Zurich, Frankfurt, Dubai and Taipei.
About the Lipper Fund Awards
The Lipper Fund Awards are part of the Thomson Reuters Awards for Excellence, a global family of awards that celebrate exceptional performance throughout the professional investment community. The Thomson Reuters Awards for Excellence recognize the world's top funds, fund management firms, sell- side firms, research analysts, and investor relations teams. The Thomson Reuters Awards for Excellence also include the Extel Survey Awards, the StarMine Analyst Awards, and the StarMine Broker Rankings. For more information, please contact markets.awards@thomsonreuters.com or visit excellence.thomsonreuters.com.
For Lipper Best Individual Funds, the calculation periods extend over 36, 60 and 120 months. The highest Lipper Leader for Consistent Return (Effective Return) value within each eligible classification determines the fund classification winner over 3, 5 or 10 years as of 12/31/13 and no other time periods. 39, 34 and 27 Global Healthcare/Biotechnology Funds were eligible for this award for the 3- 5- and 10-year period respectively. Only eligible investors may purchase Class D Shares. See a prospectus for eligibility requirements and other available share classes.
The health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.
Foreign securities have additional risks including exchange rate changes, political and economic upheaval, the relative lack of information, relatively low market liquidity and the potential lack of strict financial and accounting controls and standards. These risks are magnified in emerging markets. The prices of foreign securities held by the fund, and therefore a fund's performance, may decline in response to such risks.
There is no assurance that the investment process will consistently lead to successful investing.
Past performance is no guarantee of future results. Call 877.33JANUS (52687) or visit janus.com/advisor/mutual-funds for current month-end performance.
Please consider the charges, risks, expenses and investment objectives carefully before investing. For a prospectus or, if available, a summary prospectus containing this and other information, please contact your investment professional or download the file from janus.com/info. Read it carefully before you invest or send money.
Janus Distributors LLC
C-0314-60031